这些结果表明阿里克伦在减轻高血压合并左室肥厚患者心脏终末损伤方面，与血管紧张素受体阻滞剂的效果类似。
These findings suggest that aliskiren was as effective as an angiotensin receptor blocker in attenuating this measure of myocardial end-organ damage in hypertensive patients with LV hypertrophy.
目前，我认为血管紧张素受体阻断剂是耐受更好的肾素-血管紧张素系统阻滞剂，因此我会在联合策略中包括这种药物。
I think at the moment, the angiotensin receptor blockers are the better tolerated blockers of the renin-angiotensin system, so I would include those in a combination.
受体阻滞剂（BB）和血管紧张素转换酶抑制剂（ACEI）的实际使用率分别为49·4%、65·4%。
The actual utilization rate of beta blockers(BB)and angiotensin-converting enzyme inhibitors(ACEI)was 49.4 and 65.4, respectively.
受体阻滞剂（BB）和血管紧张素转换酶抑制剂（ACEI）的实际使用率分别为49·4%、65·4%。
The actual utilization rate of beta blockers(BB)and angiotensin-converting enzyme inhibitors(ACEI)was 49.4 and 65.4, respectively.
应用推荐